Selected References

• Bruckmaier R, et al. 1991. Effects of alpha- and beta-adrenergic agonists in intramammary pressure and milk flow in dairy cows. J Dairy Res. 58:411-419.
• Cottle MKW, et al. 1982. Effects of phenylephrine and sodium salicylate on maternal and fetal cardiovascular indices and blood oxygenation in sheep. Am J Obstet Gynecol. 143:170-176.
• Gilbert-Barness E, Drut RM. 2000. Association of sympathomimetic drugs with malformations. Vet Hum Toxicol. 42:168-171.
• Heinonen OP, et al. 1977. Birth Defects and Drugs in Pregnancy, Littleton, Publishing Sciences Group, pp 345-356, 439, 476, 491.
• Mohta M, et al. 2022. Neonatal outcomes following phenylephrine or norepinephrine for treatment of spinal anesthesia-induced hypotension at emergency cesarean section in women with fetal compromise: a randomised controlled study. Int J of Obstet Anesthesia 49:103247.
• Rothman KJ, et al. 1979. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol. 109:433-439.
• Schatz M, et al. 1997. Asthma and allergy in pregnancy. Clin Perinatol. 24(2):407-432.
• Ugen KE, Scott WJ Jr. 1987. Reduction of uterine blood flow by phenylephrine, an alpha-adrenergic agonist, in the day 11 pregnant rat: relationship to potentiation of acetazolamide teratogenesis. Teratology. 36(1):133-141.
• Yau W-P, et al. 2013. Use of decongestants during pregnancy and the risk of birth defects. Am J Epidemiol. 178(2):198-208.
• Werler MM, et al. 2003. Association of vasoconstrictive exposures with risks of gastroschisis and small intestinal atresia. Epidemiology. 14(3):349-354.
• Werler MM, et al. 2002. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol. 155(1):26-31.
• Werler MM, et al. 2004. Vasoactive exposures, vascular events, and hemifacial microsomia. Birth Defects Res A Clin Mol Teratol 70(6):389-395.
• Zierler S, Rothman KJ. 1985. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy. N Engl J Med. 313:347-352

Selected References:

• Ahn HK, et al. 2007. Exposure to amlodipine in the first trimester of pregnancy and during breastfeeding. Hypertension in pregnancy, 26(2):179–187.
• Aoki H, et al. 2018. Low Levels of Amlodipine in Breast Milk and Plasma. Breastfeeding medicine,13(9):622–626.
• Centers for Disease Control and Prevention. (2024). Health and economic benefits of high blood pressure interventions. Retrieved August 2024 from https://www.cdc.gov/nccdphp/priorities/high-blood-pressure.html.
• Faham DE, et al. 2019. Can Amlodipine Improve the Pre-ovulatory Follicle Blood Flow in Women with Polycystic Ovarian Syndrome?. Journal of reproduction & infertility, 20(2):89–94.
• Ishikawa T, et al. 2023. Risk of major congenital malformations associated with first-trimester antihypertensives, including amlodipine and methyldopa: A large claims database study 2010-2019. Pregnancy hypertension, 31:73–83.
• Magee LA, et al. 1996. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. Am J Obstet Gynecol, 174(3):823-828.
• Mito AA, et al. 2019. Safety of Amlodipine in Early Pregnancy. Journal of the American Heart Association, 8(15):1-7.
• Morgan JL, et al. 2018. Pharmacokinetics of amlodipine besylate at delivery and during lactation. Pregnancy hypertension, 11:77–80.
• Naito T, et al. 2015. Amlodipine passage into breast milk in lactating women with pregnancy-induced hypertension and its estimation of infant risk for breastfeeding. Journal of human lactation, 31(2):301–306.
• Rosbotham JL, et al. 1998. Painful subcutaneous fat necrosis of the newborn associated with intra-partum use of a calcium channel blocker. Clinical and experimental dermatology. 23(1):19–21.
• Szucs KA, et al. 2010. Maternal membranous glomerulonephritis and successful exclusive breastfeeding. Breastfeeding Medicine, 5(3):123–126.
• S. Food and Drug Administration. (2011). Norvasc (Amlodipine besylate) tablets label. Retrieved August 2024 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s047lbl.pdf.
• Vigil-De Gracia P, et al. 2014. Management of chronic hypertension during pregnancy with furosemide, amlodipine or aspirin: a pilot clinical trial. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 27(13): 1291–1294.
• Yin J, et al. 2022. Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. Archives of Gynecology and Obstetrics, 306(6):1891–1900.

Selected References:

• Auffret M, et al. 2016. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol, 207:188-192.
• Baev OR, et al. 2017. Outcomes of mifepristone usage for cervical ripening and induction of labour in full-term pregnancy. Randomized controlled trial. Eur J Obstet Gynecol Reprod Biol, 217:144-149.
• Brown A, et al. 2002. Daily low dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomised controlled trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab, 87:63-70.
• Bos-Thompson MA, et al. 2008. Mobius syndrome in a neonate after mifepristone and misoprostol elective abortion failure. Ann Pharmacother, 42(6):888-892.
• Chen A, et al. 2004. Mifepristone-induced early abortion and outcome of subsequent wanted pregnancy. Am J Epidemiol, 160(2):110-117.
• Gary MM, Harrison DJ. 2006. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann Pharmacother, 40:191-197.
• Glasier A, et al. 1992. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med, 327:1041-1044.
• Juneja SC, Dodson MG. 1990. In vitro effect of RU 486 on sperm-egg interaction in mice. Am J Obstet Gynecol, 163:216-221.
• Lakha F, et al. 2007. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum Reprod, 22(9):2428-2436.
• Liao H, et al. 2011. Repeated medical abortions and the risk of preterm birth in the subsequent pregnancy. Arch Gynecol Obstet, 284(3):579-586.
• Lim BH, et al. 1990. Normal development after exposure to mifepristone in early pregnancy. Lancet, 336:257-258.
• Mifepristone Drug Label. 2023. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b63fad9b-7f12-4400-9019-b0586054e534.
• Peyron R, et al. 1993. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med, 328:1509-1513.
• Pons JC, et al. 1991. Development after exposure to mifepristone in early pregnancy. Lancet; 338:763.
• Saav I, et al. 2010. Medical abortion in lactating women–low levels of mifepristone in breast milk. Acta Obstet Gynecol Scand, 89(5):618-622.
• Sanchez-Criado JE, et al. 1990. A possible dual mechanism of the anovulatory action of antiprogesterone RU486 in the rat. Biol Reprod, 42:877-886.
• Shoupe D, et al. 1987. Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase. Am J Obstet Gynecol, 157:1421-1426.
• Sitruk-Ware R, Davey A, Sakiz E. 1998. Fetal malformations and failed medical termination of pregnancy. Lancet, 352:323.
• Swahn ML, et al. 1996. Contraception with anti-progesterone. Baillieres Clin Obstet Gynaecol, 10(1):43-53.
• Task force on postovulatory methods of fertility regulation. 1999. Comparison of three single doses of mifepristone as emergency contraception: a randomised trial. Lancet 353:607-702.
• van der Schoot P, et al.1987. Effects of the progesterone antagonist RU486 on ovarian activity in the rat. Endocrinology, 121:1375-1382.
• Wolf JP. et al. 1990. Tolerance of perinidatory primate embryos to RU 486 exposure in vitro and in vivo. Contraception, 41:85-92.
• Yang YQ, Wu JT. 1990. RU 486 interferes with egg transport and retards the in vivo and in vitro development of mouse embryos. Contraception, 41:551-556.
• Zhu QX, et al. 2009. Mifepristone-induced abortion and placental complications in subsequent pregnancy. Hum Reprod, 24(2):315-319.

Selected References:

• American College of Obstetricians and Gynecologists (ACOG). 2022/Apr. Preeclampsia and High Blood Pressure during Pregnancy. https://www.acog.org/womens-health/faqs/preeclampsia-and-high-blood-pressure-during-pregnancy
• Anderson PO, et al 2020. Drug treatment of Raynaud’s phenomenon of the nipple. Breastfeed Med 15:686-8.
• Benoff S, et al. 1994. The effect of calcium ion channel blockers on sperm fertilization potential. Fertil Steril 62:606-17.
• Bortolus R, et al. 2000. Nifedipine administered in pregnancy: Effect on the development of children at 18 months. BJOG 107:792-794.
• Davis RL, et al 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmocoepidemiol Drug Saf 20:13-145.
• Dublin S, et al. 2022. Maternal and neonatal outcomes of antihypertensive treatment in pregnancy: a retrospective cohort study. PLoS One 17(5):e0268284
• George R, et. 2022. Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 40(10):1876-1886.
• Houtzager BA, et al. 2006. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG. 2006 Mar; 113(3):324-31.
• Magee LA, et al. 1996. The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study. Am J Obstet Gynecol 174:823-828.
• Malfará BN, et al. 2019. ABCG2 c.421C>A polymorphism alters nifedipine transport to breast milk in hypertensive breastfeeding women. Reprod Toxicol 85:1-5.
• Penny WJ, Lewis MJ. 1989. Nifedipine is excreted in human milk. Eur J Clin Pharmacol. 36(4):427-8.
• Tabacova SA, et al. 2002. Developmental abnormalities reported to FDA in association with nifedipine treatment in pregnancy. Teratology; 65:368.
• Taddio A, et al 1996. Is nifedipine use during labor and breast-feeding safe for the neonate? Clin Investig Med 19:S11. Abstract.
• Weber-Schoendorfer C, et al. 2008. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. Reprod Toxicol 26(1): 24-30.
• Wu M, et al 2012. Raynaud’s phenomenon of the nipple. Obstet Gynecol. 119(2 Pt 2):447-9.

• Agrawal M, et al. 2022. Antithyroid drug therapy in pregnancy and risk of congenital anomalies: Systematic review and meta-analysis. Clinical endocrinology, 96(6):857–868.
• Akmal A, Kung J. 2014. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. Expert Opin Drug Saf, 13(10):1397-1406.
• Alexander EK, et al. 2017. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid: official journal of the American Thyroid Association, 27(3):315–389.
• American College of Obstetricians and Gynecology. 2020. Thyroid disease in pregnancy. ACOG Practice Bulletin, Number 223. Obstet Gynecol, 135(6):e261-e274.
• Andersen SL, et al. 2013. Birth Defects after early pregnancy use of antithyroid drugs: A Danish nationwide study. J Clin Endocrinol Metab, 98(11):4374-4381.
• Andersen SL, et al. 2017. Birth Defects after early pregnancy use of antithyroid drugs: A Swedish nationwide study. Euro J Endocrinol, 177(4):369-378.
• Andersen SL, Andersen S. 2020. Antithyroid drugs and birth defects. Thyroid Res, 13:11.
• Arata N, et al. 2012. Pregnancy outcomes of exposure to methimazole (POEM) study: an interim report. Japanese journal of clinical medicine, 70(11):1976-1982.
• Awosika AO, et al. 2023. Methimazole. StatPearls [Internet], Treasure Island (FL), available from: https://www.ncbi.nlm.nih.gov/books/NBK545223/
• Azizi F. 2003. Thyroid function in breast-fed infants is not affected by methimazole-induced maternal hypothyroidism: results of a retrospective study. J Endocrinol Invest, 26:301-304.
• Baid SK, Merke DP. 2007. Aplasia cutis congenita following in utero methimazole exposure. J Pediatr Endocrinol Metab, 20:585-586.
• Barbero P, et al. 2008. Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. Am J Med Genet, 146A(18):2390-2395.
• Cassina M, et al. 2012. Pharmacologic treatment of hyperthyroidism during pregnancy. Birth Defects Res A Clin Mol Teratol, 94(8):612-619.
• Chan GW, Mandel SJ. 2007. Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab; 3(6):470-8.
• Chen CH, et al. 2011. Risk of adverse perinatal outcomes with antithyroid treatment during pregnancy: a nationwide population-based study. BJOG, 118:1365-1373.
• Clementi M, et al. 1999. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet, 83:43-46.
• Committee on Drugs, American Academy of Pediatrics. 2001. The transfer of drugs and other chemicals into human breast milk. Pediatrics, 108:776-789.
• Cooper DS. 1987. Antithyroid drugs: to breast-feed or not to breast-feed. Am J Obstet Gynecol, 157:234-235.
• Diav-Citrin O, Ornoy A. 2002. Teratogen update: antithyroid drugs-methimazole, carbimazole, and propylthiouracil. Teratology, 65:38-44.
• Di Gianantonio E, et al. 2001. Adverse effects of prenatal methimazole exposure. Teratology, 64(5):262–266.
• Dumi M, et al. 2002. Choanal stenosis, hypothelia, deafness, recurrent dacryocystitis, neck fistulas, short stature, and microcephaly: report of a case. Am J Med Genet, 113:295-297.
• Dumitrascu MC, et al. 2021. Hyperthyroidism management during pregnancy and lactation (Review). Exp Ther Med, 22(3):960.
• Eisenstein Z, et al. 1992. Intellectual capacity of subjects exposed to methimazole or propylthiouracil in utero. Eur J Pediatr, 151:558-559.
• Ferraris S, et al. 2003. Malformations following methimazole exposure in utero: an open issue. Birth Defects Res (Part A), 67:989-992.
• Francis T, et al. 2020. Safety of antithyroid drugs in pregnancy: update and therapy implications. Expert Opin Drug Saf, 19(5):565-576.
• Gianetti E, et al. 2015. Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest, 38(9):977-985.
• Greenberg F. 1987. Brief clinical report: Choanal atresia and athelia: Methimazole teratogenicity or a new syndrome? Am J Med Genet, 28:931-934.
• Gripp KW, et al. 2011. Grade 1 microtia, wide anterior fontanel and novel type trachea-esophageal fistula in methimazole embryopathy. Am J Med Genet A, 155A(3):526-533.
• Howley MM, et al. 2017. Thyroid medication use and birth defects in the National Birth Defects Prevention Study. Birth Defects Res, 109(18):1471-1481.
• Hudzik B, Zubelewicz-Szkodzinska B. 2016. Antithyroid drugs during breastfeeding. Clin Endocrinol (Oxf), 85(6):827-830.
• Johnsson E, et al. 1997. Severe malformations in infant born to hyperthyroid woman on methimazole. Lancet, 350:1520.
• Karlsson FA, et al. 2002. Severe embryopathy and exposure to methimazole in early pregnancy. J Clin Endocrinol Metab, 87(2):947-949.
• Korelitz JJ, et al. 2013. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. Thyroid, 23:758-765.
• Martin-Denavit T, et al. 2000. Ectodermal abnormalities associated with methimazole intrauterine exposure [letter]. Am J Med Genet, 94:338-340.
• Methimazole tablets, USP Prescribing Information. Par Pharmaceutical Companies, Inc. Spring Valley, NY 10977. Accessed May 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/040350s016lbl.pdf
• Mitsuda N, et al. 1992. Risk factors for developmental disorders in infants born to women with Graves disease. Obstet Gynecol; 80(3 Pt 1):359-64.
• Momotani M, et al. 1984. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxford), 20:695-700.
• Purnamasari D, et al. 2019. Gastroschisis Following Treatment with High-Dose Methimazole in Pregnancy: A Case Report. Drug Saf Case Rep, 6(1):5.
• Radetti G, et al. 2002. Foetal and neonatal thyroid disorders. Minerva Pediatr; 54(5):383-400.
• Rasmussen SA, et al. 2007. Maternal thyroid disease as a risk factor for craniosynostosis. Obstetrics and gynecology, 110(2 Pt 1):369–377.
• Romeo AF, Obican SG. 2020. Teratogen Update: Antithyroid Medications. Birth Defects Res, 112(15):1150-1170.
• Sargent KA, et al. 1994. Apparent scalp-ear-nipple (Findlay) syndrome in a neonate exposed to methimazole in-utero. Am J Hum Genet, 55:A312.
• Sato Y, et al. 2014. A case of fetal hyperthyroidism treated with maternal administration of methimazole. J Perinatol, 34(12):945-347.
• Seo GH, et al. 2018. Antithyroid drugs and congenital malformations. A nationwide Korean cohort study. Ann Intern Med, 168(6):405-413.
• Seoud M, et al. 2003. Gastrointestinal malformations in two infants born to women with hyperthyroidism untreated in the first trimester. Am J Perinatol, 20:59-62.
• Shepard TH, et al. 2002. Update on new developments in the study of human teratogens. Teratology, 65(4):153–161.
• Stagnaro-Green A, et al. 2011. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid, 21:1081-1125.
• Tegler L, Lindstrom B. 1980. Antithyroid drugs in milk. Lancet, 2:591.
• The WHO Working Group, Bennet PN (ed). 1988. Drugs and Human Lactation. Elsevier, Amsterdam, New York, Oxford, pp. 196-197.
• Tonacchera M, et al. 2020. Treatment of Graves’ hyperthyroidism with thionamides: a position paper on indications and safety in pregnancy. J Endocrinol Invest, 43(2):257-265.
• Wilson LC, et al. 1998. Choanal atresia and hypothelia following methimazole exposure in utero: a second report. Am J Med Genet, 75:220-222.